Should be announced in about two weeks by March 13th and will be interesting to see if they partnered with an Eu company that would be able to grow the company at an higher rate then it currently is running at present. Would that mean an buyout? Not necessarily and like Abreva which partnered with GSK I suspect that KK will want an much better deal with Nuedexta. This might make a few even recall when they wanted the name Zenvia but were told that would not be zcceptable to the FDA back in 2010! I'd sure like to see this get back to that approval SP rate when it was over $5 and if things go smoothly over there, it would not surprize me to see KK see the whole kit & kaboodle for around $15! A pretty handsome buyout price that would seem like an dream but you add EU approval and it's not that far fetched!